---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-042756"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:03:52.647047+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial

## Summary
- Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.
- NDA for VP-102 (molluscum contagiosum) resubmitted Jan 23, 2023; PDUFA goal date expected H2 2023.
- New CMO partner Piramal Pharma Solutions selected; technology transfer completed Jan 2023.
- VP-315 Phase 2 Part 1 (10 patients) showed favorable safety, no serious adverse events; Part 2 to start Q2 2023.
- Phase 3 trial for VP-102 (external genital warts) expected to initiate H2 2024.

## SEC filing metadata
- accession: 0001193125-23-042756
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/0001193125-23-042756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/d467166d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-042756
- JSON: https://secwatch.observer/filing/0001193125-23-042756.json
- Plain text: https://secwatch.observer/filing/0001193125-23-042756.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported preliminary financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: preliminary results
  source text: On February 21, 2023, Verrica Pharmaceuticals Inc. (the “ Company ”) reported that, as of December 31, 2022, it had approximately $34.3 million of cash and cash equivalents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/0001193125-23-042756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.